Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IeM.

J Natl Cancer Inst. 2012 Oct 3;104(19):1503-13. doi: 10.1093/jnci/djs345. Epub 2012 Aug 23.

2.

Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.

Kuhn E, Bahadirli-Talbott A, Shih IeM.

Mod Pathol. 2014 Jul;27(7):1014-9. doi: 10.1038/modpathol.2013.209. Epub 2013 Dec 6.

3.

Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.

Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, Liles G, Karlan B, Köbel M, Lee CH, Soslow RA.

Mod Pathol. 2015 Apr;28(4):505-14. doi: 10.1038/modpathol.2014.143. Epub 2014 Nov 14.

4.

Amplicon profiles in ovarian serous carcinomas.

Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih IeM, Wang TL.

Int J Cancer. 2007 Jun 15;120(12):2613-7.

5.

CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.

Nakayama K, Rahman MT, Rahman M, Nakamura K, Ishikawa M, Katagiri H, Sato E, Ishibashi T, Iida K, Ishikawa N, Kyo S.

Int J Oncol. 2016 Feb;48(2):506-16. doi: 10.3892/ijo.2015.3268. Epub 2015 Nov 26.

6.

Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.

Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K; Children's Cancer and Leukaemia Group.; SIOP Wilms' Tumour Biology Group..

Clin Cancer Res. 2010 Apr 1;16(7):2036-45. doi: 10.1158/1078-0432.CCR-09-2890. Epub 2010 Mar 23.

7.

Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.

Mahdi H, Xiu J, Reddy SK, DeBernardo R.

J Surg Oncol. 2015 Aug;112(2):188-94. doi: 10.1002/jso.23993. Epub 2015 Aug 7.

PMID:
26250968
8.

PPP2R1A mutations are common in the serous type of endometrial cancer.

Nagendra DC, Burke J 3rd, Maxwell GL, Risinger JI.

Mol Carcinog. 2012 Oct;51(10):826-31. doi: 10.1002/mc.20850. Epub 2011 Aug 31.

PMID:
21882256
9.

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.

10.

Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.

Shih IeM, Wang TL.

J Pathol. 2011 May;224(1):1-4. doi: 10.1002/path.2884. Epub 2011 Mar 22.

PMID:
21432855
11.

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.

Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K; ANECS., Akslen LA, Claes B, Vergote I, Moerman P, Van Robays J, Marcickiewicz J, Salvesen HB, Spurdle AB, Amant F.

Gynecol Oncol. 2013 Feb;128(2):327-34. doi: 10.1016/j.ygyno.2012.11.037. Epub 2012 Dec 4.

PMID:
23219661
12.

Whole exome sequence analysis of serous borderline tumors of the ovary.

Boyd J, Luo B, Peri S, Wirchansky B, Hughes L, Forsythe C, Wu H.

Gynecol Oncol. 2013 Sep;130(3):560-4. doi: 10.1016/j.ygyno.2013.06.007. Epub 2013 Jun 14.

13.

Landscape of genomic alterations in cervical carcinomas.

Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Treviño V, Vazquez-Santillan K, Guadarrama AS, Wright AA, Rosenberg MW, Duke F, Kaplan B, Wang R, Nickerson E, Walline HM, Lawrence MS, Stewart C, Carter SL, McKenna A, Rodriguez-Sanchez IP, Espinosa-Castilla M, Woie K, Bjorge L, Wik E, Halle MK, Hoivik EA, Krakstad C, Gabiño NB, Gómez-Macías GS, Valdez-Chapa LD, Garza-Rodríguez ML, Maytorena G, Vazquez J, Rodea C, Cravioto A, Cortes ML, Greulich H, Crum CP, Neuberg DS, Hidalgo-Miranda A, Escareno CR, Akslen LA, Carey TE, Vintermyr OK, Gabriel SB, Barrera-Saldaña HA, Melendez-Zajgla J, Getz G, Salvesen HB, Meyerson M.

Nature. 2014 Feb 20;506(7488):371-5. doi: 10.1038/nature12881. Epub 2013 Dec 25.

14.

FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.

Kitade S, Onoyama I, Kobayashi H, Yagi H, Yoshida S, Kato M, Tsunematsu R, Asanoma K, Sonoda K, Wake N, Hata K, Nakayama KI, Kato K.

Cancer Sci. 2016 Oct;107(10):1399-1405. doi: 10.1111/cas.13026. Epub 2016 Sep 24.

15.

TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.

Zheng H, Wang Y, Tang C, Jones L, Ye H, Zhang G, Cao W, Li J, Liu L, Liu Z, Zhang C, Lou F, Liu Z, Li Y, Shi Z, Zhang J, Zhang D, Sun H, Dong H, Dong Z, Guo B, Yan HE, Lu Q, Huang X, Chen SY.

Cancer Genomics Proteomics. 2016 May-Jun;13(3):231-8.

PMID:
27107065
16.

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.

Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, Sgroi DC; NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program., Hieter P, Mullikin JC, Merino MJ, Bell DW.

Nat Genet. 2012 Dec;44(12):1310-5. doi: 10.1038/ng.2455. Epub 2012 Oct 28.

17.

Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.

Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group..

Int J Gynecol Cancer. 2014 Mar;24(3):468-77. doi: 10.1097/IGC.0000000000000089.

PMID:
24557434
18.

BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.

Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH, Kern SE.

Am J Pathol. 2003 Oct;163(4):1255-60.

19.

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Black JD, English DP, Roque DM, Santin AD.

Womens Health (Lond). 2014 Jan;10(1):45-57. doi: 10.2217/whe.13.72. Review.

20.

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A; Australian Ovarian Cancer Study (AOCS)..

Clin Cancer Res. 2014 Dec 15;20(24):6618-30. doi: 10.1158/1078-0432.CCR-14-1292. Epub 2014 Oct 14. Erratum in: Clin Cancer Res. 2016 Aug 15;22(16):4272.

Supplemental Content

Support Center